Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 3Recurrence 1Breast Cancer Metastatic 1

Interventions

Fulvestrant 5Letrozole 3Capecitabine 3ribociclib 2exemestane 2dalpiciclib 2apatinib 2Irinotecan 2Gemcitabine 2Anastrozole 2tusamitamab ravtansine 1trastuzumab deruxtecan 1sacituzumab govitecan 1pegfilgrastim 1palbociclib 1margetuximab 1irinotecan sucrosofate 1fluzoparib 1abemaciclib 1Vinorelbine 1Trastuzumab 1Tamoxifen 1Paclitaxel 1Liposomes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Cancer Metastatic × margetuximab × Clear all
NCT04262804 2023-08-22

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Zai Lab (Hong Kong), Ltd.

Phase 2 Unknown
123 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡